Summary & Overview
CPT 0180U: Navigator ABO Sequencing Test for ABO Blood Group Antigens
CPT code 0180U designates a Proprietary Laboratory Analyses (PLA) test — the Navigator ABO Sequencing assay from Grifols Immunohematology Center — used to determine ABO blood group antigens by sequencing specific gene regions. This molecular test addresses clinical needs for accurate blood typing to reduce the risk of incompatible blood transfusions, guide organ transplant compatibility assessments, and inform perinatal and neonatal care. Nationally, PLA codes like 0180U matter because they identify manufacturer- or lab-specific diagnostics that can have implications for coverage policies, prior authorization, and lab network contracting.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for ABO sequencing, typical sites of service, and the kinds of benchmarks and policy issues commonly associated with PLA codes — including coverage criteria, coding guidance, and payer adjudication patterns. The publication also outlines where data are available and where input was not provided. This summary equips clinicians, billing professionals, and policy analysts with the essential facts about CPT code 0180U and the operational considerations for its use in clinical laboratory settings.
Billing Code Overview
CPT code 0180U is a Proprietary Laboratory Analyses (PLA) code for the Navigator ABO Sequencing test from Grifols Immunohematology Center. The test analyzes specific gene sequences to determine ABO blood group antigens, which can help clinicians minimize adverse blood–type incompatibility reactions in blood transfusions, organ transplants, and in pregnancy and newborn care.
-
Service type: Genetic sequencing-based blood group antigen analysis
-
Typical site of service: Clinical laboratory setting (specimen such as blood)
Clinical & Coding Specifications
Clinical Context
A patient scheduled for a complex transfusion evaluation or pre-transplant compatibility workup presents to a hospital transfusion medicine service or an immunohematology reference laboratory. A specimen of whole blood is collected and sent to the specialized laboratory for the Navigator ABO Sequencing test (0180U) to determine ABO gene sequence variants that influence blood group antigen expression. Typical indications include resolving discrepant or weak ABO serologic typing results, investigation of hemolytic disease of the fetus and newborn, pre-transfusion assessment for patients with a history of transfusion reactions, and pre-transplant donor–recipient compatibility evaluation. The clinical workflow begins with clinician order entry and specimen collection using standard blood bank tubes, couriered to the Grifols Immunohematology Center. The laboratory performs nucleic acid extraction, targeted sequencing of the ABO gene regions specified by the proprietary assay, bioinformatic analysis, and result reporting to the requesting transfusion medicine physician, hematologist, obstetrician, or transplant team. Results inform selection of compatible blood products, guide prenatal counseling when maternal–fetal ABO incompatibility is suspected, and assist transplant teams in minimizing ABO-related graft risks.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When billing separates the interpretation/professional analysis from the technical laboratory component |